Vivani's Semaglutide Implant Shows Year-Long >20% Weight Loss in Preclinical Data, Advances to Phase 1
VANI sits 18% above its 52-week low of $0.905.
Summary
Vivani Medical announced strong preclinical results for its NPM-139 semaglutide implant, demonstrating sustained semaglutide exposure and over 20% sham-adjusted weight loss for a full year with a single administration. This significant data, coupled with the successful completion of the LIBERATE-1 first-in-human study, is advancing NPM-139 towards a Phase 1 clinical study expected to initiate in mid-2026 with results anticipated by year-end. For a clinical-stage biopharmaceutical company, these positive developments in a highly sought-after GLP-1 market are a major de-risking event and a strong positive catalyst. The company also confirmed a solid cash position, supporting operations into mid-2027 and enabling the completion of these key milestones. Investors will closely monitor the initiation and results of the upcoming Phase 1 study for NPM-139.
At the time of this announcement, VANI was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.8M. The 52-week trading range was $0.91 to $1.92. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.